Avality, the first fast-acting antidepressant.

Or is it?

Today, we look at four controversies with this dextromothorfen bupropion combo.

Welcome to the Carlyte Psychiatry Podcast, keeping psychiatry honest since 2003.

I'm Chris Sagan, the editor-in-chief of the Carlat Psychiatry Report.

And I'm Kelly Newsom, a psychiatric MP and a dedicated reader of every issue.

We pick up again with a velity.

The med that augments with velocity.

Last week, we learned this combination of Euproprproprion and dextromothorfin

does indeed work fast, within a week, and is more effective than buproprion alone.

But despite those accolades, it missed the mark in treatment-resistant depression.

Today, we're going to talk about its side effects and cover four

controversies with the drug. One, is it addictive? Two, does it work long term? Three, can you just

use a generic components? And four, is it really any different from a popular speed up strategy

from the 1980s?

We're going to start with its side effects, but first, a preview of the CME quiz for this episode.

What is the main risk of combining dextromithorfan with other antidepressants besides buproprion? A. Neuroleptic malignant syndrome.

B. Only buproprion will inhibit dextramathorphans metabolism.

C.

Serotonin syndrome.

Or D.

neurotoxicity. In last week's episode, we learned that dextromythorfen makes buproprion work faster and boosts its

...